Your browser doesn't support javascript.
loading
Simplified Cas13-based assays for the fast identification of SARS-CoV-2 and its variants.
Arizti-Sanz, Jon; Bradley, A'Doriann; Zhang, Yibin B; Boehm, Chloe K; Freije, Catherine A; Grunberg, Michelle E; Kosoko-Thoroddsen, Tinna-Solveig F; Welch, Nicole L; Pillai, Priya P; Mantena, Sreekar; Kim, Gaeun; Uwanibe, Jessica N; John, Oluwagboadurami G; Eromon, Philomena E; Kocher, Gregory; Gross, Robin; Lee, Justin S; Hensley, Lisa E; MacInnis, Bronwyn L; Johnson, Jeremy; Springer, Michael; Happi, Christian T; Sabeti, Pardis C; Myhrvold, Cameron.
Affiliation
  • Arizti-Sanz J; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Bradley A; Harvard-MIT Program in Health Sciences and Technology, Cambridge, MA, USA.
  • Zhang YB; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Boehm CK; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Freije CA; Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA.
  • Grunberg ME; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Kosoko-Thoroddsen TF; Department of Molecular Biology, Princeton University, Princeton, NJ, USA.
  • Welch NL; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Pillai PP; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Mantena S; Department of Molecular Biology, Princeton University, Princeton, NJ, USA.
  • Kim G; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Uwanibe JN; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • John OG; Program in Virology, Harvard Medical School, Boston, MA, USA.
  • Eromon PE; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Kocher G; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Gross R; Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA.
  • Lee JS; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Hensley LE; Department of Molecular Biology, Princeton University, Princeton, NJ, USA.
  • MacInnis BL; African Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer's University, Ede, Osun State, Nigeria.
  • Johnson J; Department of Biological Sciences, College of Natural Sciences, Redeemer's University, Ede, Osun State, Nigeria.
  • Springer M; Department of Biological Sciences, College of Natural Sciences, Redeemer's University, Ede, Osun State, Nigeria.
  • Happi CT; African Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer's University, Ede, Osun State, Nigeria.
  • Sabeti PC; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institute of Health, Frederick, MD, USA.
  • Myhrvold C; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institute of Health, Frederick, MD, USA.
Nat Biomed Eng ; 6(8): 932-943, 2022 08.
Article in En | MEDLINE | ID: mdl-35637389
ABSTRACT
The widespread transmission and evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) call for rapid nucleic acid diagnostics that are easy to use outside of centralized clinical laboratories. Here we report the development and performance benchmarking of Cas13-based nucleic acid assays leveraging lyophilised reagents and fast sample inactivation at ambient temperature. The assays, which we named SHINEv.2 (for 'streamlined highlighting of infections to navigate epidemics, version 2'), simplify the previously reported RNA-extraction-free SHINEv.1 technology by eliminating heating steps and the need for cold storage of the reagents. SHINEv.2 detected SARS-CoV-2 in nasopharyngeal samples with 90.5% sensitivity and 100% specificity (benchmarked against the reverse transcription quantitative polymerase chain reaction) in less than 90 min, using lateral-flow technology and incubation in a heat block at 37 °C. SHINEv.2 also allows for the visual discrimination of the Alpha, Beta, Gamma, Delta and Omicron SARS-CoV-2 variants, and can be run without performance losses by using body heat. Accurate, easy-to-use and equipment-free nucleic acid assays could facilitate wider testing for SARS-CoV-2 and other pathogens in point-of-care and at-home settings.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nucleic Acids / COVID-19 Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Nat Biomed Eng Year: 2022 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nucleic Acids / COVID-19 Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Nat Biomed Eng Year: 2022 Document type: Article Affiliation country: